LT4.F LIQUIDIA CORP. DL-001

Healthcare Biotechnology Frankfurt Exchange
49.41 EUR
Close of Nov 12, 2026
21.87 80.38
Market cap
EUR 4.45B
P/E
-
P/B
20.16x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LT4.F undervalued?

Graham number

The Graham number of LIQUIDIA CORP. DL-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LIQUIDIA CORP. DL-001 fundamental analysis

No fundamental analysis for LIQUIDIA CORP. DL-001 yet.

LIQUIDIA CORP. DL-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LIQUIDIA CORP. DL-001

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered th…

Full company profile